该杂志前身为 REVISTA BRASILEIRA DE REUMATOLOGIA，正在庆祝其出版 60 周年。ADVANCES IN RHEUMATOLOGY 是一本国际性的开放获取期刊，发表关于儿科和成人风湿病各个方面的临床前、转化和临床研究，包括退行性、炎症性和自身免疫状况。该杂志是巴西风湿病学会的官方出版物，欢迎原创研究（包括系统评价和荟萃分析）、文献综述、指南和来自已发表材料的信件。

Advances in Rheumatology, formerly known as REVISTA BRASILEIRA DE REUMATOLOGIA, is celebrating its 60th anniversary. This international open-access journal publishes preclinical, translational, and clinical research on all aspects of pediatric and adult rheumatology, including degenerative, inflammatory, and autoimmune conditions. It is the official publication of the Brazilian Society of Rheumatology and welcomes original research (including systematic reviews and meta-analyses), literature reviews, guidelines, and letters from published materials.

《Advances in Rheumatology》前身为《REVISTA BRASILEIRA DE REUMATOLOGIA》，现已庆祝出版60周年。该期刊是一本国际性的开放获取期刊，专注于儿科和成人风湿病的各个方面，涵盖临床前、转化和临床研究，包括退行性、炎症性和自身免疫性疾病。该杂志是巴西风湿病学会的官方出版物，欢迎原创研究（包括系统评价和荟萃分析）、文献综述、指南以及来自已发表材料的信件。

Advances in Rheumatology

Abstract Objectives To investigate the diagnostic performance of single-source dual-energy computed tomography (DECT) based on gemstone spectral imaging technology (including Discovery CT750HD and Revolution CT) in patients with suspected feet/ankles gouty arthritis, and evaluate the urate deposition with a novel semi-quantitative DECT scoring system. Methods A total of 196 patients were consecutively included. Feet and ankles were evaluated in all patients by single-source DECT scan. The 2015 EULAR/ACR criteria were used as the reference for the diagnosis of gout. The sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of DECT for the diagnosis of gout in the early (≤1 year), middle (1–3 years), and late (&gt; 3 years) disease durations were calculated. Besides, a novel semi-quantitative DECT scoring system was assessed for the measurement of urate deposition, and the correlation between the scores and the clinical and serological data were also evaluated. Moreover, the influences of artifacts on the diagnostic performance of DECT were also determined. Results The sensitivity, specificity, and AUC of DECT in 196 patients were 38.10, 96.43%, and 0.673 in the early-stage group; 62.96, 100.00%, and 0.815 in the middle-stage group; and 77.55, 87.50%, and 0.825 in the late-stage group, respectively. The overall diagnostic accuracies in the AUC of DECT (Discovery CT750HD and Revolution CT) in the middle and late stages of gout were higher than that in the early stage of gout. Besides, the monosodium urate crystals were deposited on the first metatarsophalangeal joints and ankles/midfeet. Age, the presence of tophus, bone erosion, and disease duration considerably affected the total urate score. No statistical difference in the positive detection of nail artifact, skin artifact, vascular calcification, and noise artifact was found between the case and control groups. Conclusion DECT (Discovery CT750HD and Revolution CT) showed promising diagnostic accuracy for the detection of urate crystal deposition in gout but had limited diagnostic sensitivity for short-stage gout. Longer disease duration, the presence of tophus, and bone erosion were associated with the urate crystal score system. The artifacts do not remarkably affect the diagnostic performance of DECT in gout.

Jin Shang

Xiao-Hu Li

Shu-Qin Lu

Yi Shang

Lu-Lu Li

Bin Liu

Gout of feet and ankles in different disease durations: diagnostic value of single-source DECT and evaluation of urate deposition with a novel semi-quantitative DECT scoring system

不同病程的足踝痛风：单源双能CT的诊断价值及新型半定量双能CT评分系统对尿酸沉积的评估

Abstract Objectives Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method Pooled data from Phase 2 (NCT01786668; 04/2013–03/2015)/Phase 3 (NCT03502616; 06/2018–08/2020) RCTs in AS patients were analyzed (3 overlapping cohorts): 16-week placebo-controlled (tofacitinib 5 mg twice daily [BID] [ n = 185]; placebo [ n = 187]); 48-week only-tofacitinib 5 mg BID ( n = 316); 48-week all-tofacitinib (≥ 1 dose of tofacitinib 2, 5, or 10 mg BID; n = 420). Baseline 10-year atherosclerotic cardiovascular disease (ASCVD) risk was determined in patients without history of ASCVD (48-week cohorts). Adverse events (AEs)/AEs of special interest were evaluated/compared with findings from other tofacitinib programs (16 Phase 2/Phase 3 rheumatoid arthritis [RA]; 2 Phase 3 psoriatic arthritis [PsA] RCTs) and a real-world cohort of AS patients initiating biologic disease-modifying antirheumatic drugs (US MarketScan). Results Most patients (&gt; 75%; 48-week cohorts) without history of ASCVD had low baseline 10-year ASCVD risk. One patient (tofacitinib 5 mg BID; in all 3 cohorts) had a serious infection (aseptic meningitis). Herpes zoster (non-serious) occurred in the 48-week only-tofacitinib 5 mg BID ( n = 5 [1.6%]) and all-tofacitinib ( n = 7 [1.7%]; one multi-dermatomal [tofacitinib 10 mg BID]) cohorts. No deaths, opportunistic infections, tuberculosis, malignancies, major adverse cardiovascular events, thromboembolic events, gastrointestinal perforations occurred. Limitations: short RCT durations/low patient numbers within cohorts. Conclusion Tofacitinib 5 mg BID was well tolerated to 48 weeks in AS patients; safety profile was consistent with RA/PsA clinical programs and a cohort of AS patients from US routine clinical practice. Clinical trial registration numbers NCT01786668 (2013-02-06); NCT03502616 (2018-04-11).

Atul Deodhar

Servet Akar

Jeffrey R. Curtis

Bassel El-Zorkany

Marina Magrey

Cunshan Wang

Joseph Wu

Solomon B. Makgoeng

Ivana Vranic

Sujatha Menon

Dona L. Fleishaker

Annette M. Diehl

Lara Fallon

Arne Yndestad

Robert B. M. Landewé

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

托法替尼在强直性脊柱炎患者II期和III期试验中的综合安全性分析

Abstract Background Despite previous studies indicating a close relationship between immune system and ankylosing spondylitis (AS), the causal relationship between them remains unclear. Methods Genome-wide association data were utilized to explore the causal link between 731 immune cells and AS using a bidirectional two-sample MR approach. The data included immune cell data from Orrù et al.’s study and AS data from the FinnGen consortium. Cochran’s Q test and leave-one-out checked instrument variable (IV) heterogeneity. IVW was the primary method for causal analysis, with MR-Egger and MR-PRESSO addressing horizontal pleiotropy. FDR correction was applied to both analysis directions to rectify multiple testing errors. Results In our study, 22 immune phenotypes out of 731 were casually linked to AS. After excluding 5 less robust features, 17 immune factors remained, with 4 being protective and the rest posing risks. Through FDR correction, we found a significant causal relationship between HLA DR on CD14- CD16+ monocyte and AS (OR (95%CI) = 0.70(0.60 ~ 0.83), P = 2.06*10 −5 ). In the reverse analysis with AS as exposure, potential effects on 34 immune features were discovered. After correction, we confirmed significant causal relationships between AS and two immune features, namely CD20- B cell %lymphocyte (OR (95%CI) = 1.16(1.08–1.25), P = 1.91*10 −5 ) and CD20- B cell %B cell (OR (95%CI) = 1.17(1.09–1.26), P = 1.50*10 −5 ). Conclusions Our study identified various features associated with AS in different types of immune cells. These findings provide important clues and a theoretical basis for further understanding the pathogenesis of AS, guiding clinical treatment, and drug design.

Ziming Geng

Yang Tong

Yang Chen

Jian Wang

Ziwen Liu

Jun Miao

Ruihua Li

Investigating the causal relationship between immune factors and ankylosing spondylitis: insights from a Mendelian Randomization study

研究免疫因素与强直性脊柱炎之间的因果关系：基于孟德尔随机化研究的见解

Abstract We investigated role of haematopoietic cell kinase (Hck) in osteoarthritis (OA) and to explore the underlying mechanisms driving its effects. An OA animal model was established and after OA induction, rats received intra-articular injections of lentivirus twice a week for four weeks. Rats were divided into four groups: control (healthy rats without OA), OA model (rats with induced OA), OA + Len-si-NC (OA rats treated with a non-targeting control lentivirus), and OA + Len-si-Hck (OA rats treated with lentivirus targeting Hck). Blood samples were collected, and serum cytokine levels were measured using ELISA. Afterward, the rats were sacrificed for histological analysis and TUNEL assay. In vitro, IL-1β-treated human chondrocytes were transfected with Hck, and the effects on cell viability, apoptosis, ECM degradation, and JAK-STAT3 signaling were assessed. Colivelin, a JAK-STAT3 agonist, was used to confirm the pathway’s involvement. Results indicated increased Hck expression in the cartilage tissues of OA rats and in IL-1β-stimulated chondrocytes. Silencing Hck i n vivo reduced IL-6 and TNF-α levels, apoptosis, and preserved cartilage structure. In vitro, Hck knockdown in IL-1β-treated chondrocytes resulted in enhanced cell viability, reduced apoptosis, and decreased ECM degradation. Notably, the expression of MMP3 and MMP13 was significantly lowered, while collagen II and aggrecan levels were restored. Additionally, Hck knockdown inhibited JAK-STAT3 activation, which was evident from reduced levels of phosphorylated JAK1 and STAT3. The addition of colivelin reversed these effects, confirming that Hck mediates its effects through the JAK-STAT3 pathway. Overall, our findings indicate that Hck is critical in OA progression by promoting inflammation, apoptosis, and ECM degradation through the JAK-STAT3 signaling pathway activation.

Zhenzhong Yan

Lin Ji

Hck promotes IL-1β-induced extracellular matrix degradation, inflammation, and apoptosis in osteoarthritis via activation of the JAK-STAT3 signaling pathway

Hck通过激活JAK-STAT3信号通路促进IL-1β诱导的骨关节炎中细胞外基质降解、炎症和细胞凋亡

Abstract Introduction The prevalence of Fibromyalgia in patients with Systemic Lupus Erythematosus (SLE) is significantly higher compared to the general population. Despite this frequent association, Fibromyalgia remains underdiagnosed and consequently inadequately treated, negatively affecting the quality of life of these patients. Objective This study aims to evaluate the occurrence of Fibromyalgia and its impact on the quality of life of Brazilian patients with SLE treated at a University Hospital in the state of Paraiba. Materials and methods This descriptive, observational, and cross-sectional study included patients with SLE diagnosed according to the 2012 criteria of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC). The occurrence of Fibromyalgia was assessed using the American College of Rheumatology (ACR) criteria of 1990 and 2010/2011, revised in 2016. Quality of life was evaluated using the Short-Form 36 (SF-36) questionnaire for all patients, while the Fibromyalgia Impact Questionnaire (FIQ) was applied to those diagnosed with Fibromyalgia. Results The sample comprised 107 SLE patients, with an average age of 54.1 years (SD:12.1), of whom 95.4% (102) were women. The prevalence of Fibromyalgia among SLE patients was 19.1% (21), all of whom were women with a mean age of 45.6 years (SD 9.6). The SF-36 scores of SLE patients with Fibromyalgia were consistently lower across all eight domains compared to those without Fibromyalgia, indicating a significant negative impact of this comorbidity. Conclusion: These findings are consistent with existing literature, highlighting the significant negative impact of Fibromyalgia on the quality of life of patients with SLE. Conclusion These findings are consistent with existing literature, highlighting the significant negative impact of Fibromyalgia on the quality of life of patients with SLE.

Jade A. M. Monteiro

Alexia L. H. Gama

Joao C. S. Oliveira

Matheus V. Falcao

Ana Karla G. Melo

Danielle C. S. Egypto

Alessandra S. Braz

Fibromyalgia comorbidity in Systemic Lupus Erythematosus patients: assessing impact on quality of life

系统性红斑狼疮患者中的纤维肌痛共病：评估对生活质量的影响

Abbreviation
Journal Impact	1.91
Quartiles(Global)	RHEUMATOLOGY(Q3)

ISSN	2523-3106
h-index	38

Publication Information	Publisher: BioMed Central Ltd，Publishing cycle: ，Journal Type: journal，Open Access Journals: Yes
Basic data	Year of publication: 2018，Proportion of original research papers: 86.36%，Self Citation Rate:0.00%， Gold OA Rate: 100.00%
Journal Fees	$2390Details
Average review cycle	网友分享经验：53 Weeks

Advances in Rheumatology

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience

Gout of feet and ankles in different disease durations: diagnostic value of single-source DECT and evaluation of urate deposition with a novel semi-quantitative DECT scoring system

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Investigating the causal relationship between immune factors and ankylosing spondylitis: insights from a Mendelian Randomization study

Hck promotes IL-1β-induced extracellular matrix degradation, inflammation, and apoptosis in osteoarthritis via activation of the JAK-STAT3 signaling pathway

Fibromyalgia comorbidity in Systemic Lupus Erythematosus patients: assessing impact on quality of life

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Investigating the causal relationship between immune factors and ankylosing spondylitis: insights from a Mendelian Randomization study

Hck promotes IL-1β-induced extracellular matrix degradation, inflammation, and apoptosis in osteoarthritis via activation of the JAK-STAT3 signaling pathway

Fibromyalgia comorbidity in Systemic Lupus Erythematosus patients: assessing impact on quality of life

Role of type 2 ryanodine receptor stabilisation in autoimmune cell modulation